|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.50 CAD | +5.80% |
|
+5.73% | +21.76% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 177M 126M 110M 102M 93.91M 12.03B 179M 1.2B 471M 6.02B 475M 465M 19.93B | P/E 2026 * |
17.4x | P/E 2027 * | 14.4x |
|---|---|---|---|---|---|
| Enterprise Value | 177M 126M 110M 102M 93.91M 12.03B 179M 1.2B 471M 6.02B 475M 465M 19.93B | EV / Sales 2026 * |
2.57x | EV / Sales 2027 * | 2.15x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | +5.80% | ||
| 1 week | +5.73% | ||
| Current month | +5.08% | ||
| 1 month | +6.90% | ||
| 3 months | +6.16% | ||
| 6 months | +12.32% | ||
| Current year | +21.76% |
| 1 week | 14.65 |  | 15.5 |
| 1 month | 14.42 | | 15.5 |
| Current year | 12.25 | | 15.8 |
| 1 year | 10.65 | | 15.8 |
| 3 years | 7.55 | | 15.8 |
| 5 years | 6.24 | | 15.8 |
| 10 years | 3.13 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/30/26 | Tax | Executive/Senior Manager | -11,359 | 0.0993% | ||
| 6/30/26 | Option | Chief Technology Officer | -600 | 0.0052% | ||
| 6/30/26 | Buy | Chief Technology Officer | -1,884 | 0.0165% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.80% | +5.73% | +35.37% | +105.30% | 126M | |
| +4.86% | -3.32% | +52.73% | +160.26% | 1,043B | |
| +1.04% | -2.99% | +50.87% | +52.38% | 621B | |
| +0.98% | -6.49% | +24.00% | +66.66% | 435B | |
| +1.96% | +0.83% | +42.80% | +37.60% | 361B | |
| -0.11% | -4.07% | +30.37% | +39.73% | 293B | |
| +2.52% | -8.36% | +7.27% | +10.32% | 251B | |
| +4.57% | +5.21% | +35.91% | +67.64% | 220B | |
| -4.32% | -12.94% | -3.79% | -44.56% | 201B | |
| -2.58% | -0.73% | +17.16% | +67.46% | 164B | |
| Average | +1.05% | -2.86% | +29.27% | +56.28% | 358.93B | |
| Weighted average by Cap. | +0.77% | -3.79% | +37.10% | +76.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49.22M 42.63M 39.74M 36.55M 4.68B 69.77M 467M 183M 2.34B 185M 181M 7.76B | 82.3M 58.71M 50.85M 47.4M 43.59M 5.58B 83.22M 557M 219M 2.79B 220M 216M 9.25B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-05 | $15.50 | +5.80% | 155,935 |
| 26-08-04 | $14.65 | -0.68% | 46,242 |
| 26-07-31 | $14.75 | +0.61% | 3,743 |
| 26-07-29 | $14.66 | -0.61% | 1,258 |
| 26-07-28 | $14.75 | +0.07% | 1,810 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.50CAD
Average target price
18.00CAD
Spread / Average Target
+16.13%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Select your edition
All financial news and data tailored to specific country editions
